Companies

Evocutis

Overview

Evocutis is the new name for Syntopix following its purchase of Leeds Skin in May 2011. It is involved in developing treatments for antibiotic resistance and diseases of the skin. Syntopix was spun-out of Leeds University in 2003 with the backing of IP Group. Syntopix joined Aim on 23 March 2006, when it raised £4m (£3.3m net) at 177p a share.

Sector: Health

News blog

• Evocutis Posted: 08/12/2014
• Evocutis Posted: 28/08/2014
• Evocutis / Venn Life Sciences Posted: 26/02/2014
• Evocutis Posted: 28/01/2014
• Evocutis Posted: 03/12/2013
• Evocutis Posted: 28/01/2013
• Evocutis Posted: 03/12/2012
• Evocutis Posted: 22/06/2012
• Evocutis Posted: 04/04/2012
• Evocutis Posted: 26/12/2011

Browse by sector

All companies

• Aim advisers
• Aim Awards
• Aim investor relations
• Cleantech
• Construction
• Consumer
• Electricals
• Financial
• Food
• Health
• Industrial
• Leisure
• Media
• Mobile
• Property
• QUOTED MICRO
• Resources
• Retail
• Security
• Services
• Technology
• Telecoms
• Training
• Transport

• 2.4mNumber of messages posted on SocialGo networks
  
• $38mCost savings generated by ideas from WalMart staff over a two month period